AstraZeneca’s Truqap Fails to Meet Primary Endpoints in Phase III Trial for Locally Advanced or Metastatic Triple-Negative Breast Cancer
The CAPItello-290 Phase III trial evaluated Truqap in combination with chemotherapy compared to placebo and chemotherapy for the treatment of locally advanced or metastatic triple-negative breast cancer.
Image Credit: Adobe Stock Images/Sebastian Kaulitzki
Results from the Phase III CAPItello-290 trial evaluating AstraZeneca’s Truqap (capivasertib) in combination with paclitaxel for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) did not meet its primary goals. According to the company, the study failed to improve overall survival (OS) compared to paclitaxel with a placebo, both in the overall patient population and in a subgroup with specific biomarker alterations (PIK3CA, AKT1, or PTEN).1
“Despite modest advances, [TNBC] remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets, and chemotherapy-based regimens continue to be the mainstay of treatment,” said Peter Schmid, MD, Barts Cancer Institute, London, UK, principal investigator of the trial, in a press release. “While the CAPItello-290 trial results have not shown what we hoped, they provide important information to further understand this aggressive form of breast cancer where patients are in urgent need of new treatments.”
Truqap is a first-in-class, potent, adenosine triphosphate-competitive inhibitor of the three AKT isoforms (AKT1/2/3). The therapy is administered at a dose of 400 mg twice daily following an intermittent dosing schedule of four days on and three days off. Truqap has been previously approved by the FDA to treat adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN) after recurrence or progression on or following an endocrine-based treatment regimen.
The double-blind, randomized CAPItello-290 trial evaluated the efficacy and safety of Truqap in combination with paclitaxel versus placebo in combination with paclitaxel in the first-line treatment of patients with locally advanced (inoperable) or metastatic TNBC. The trial enrolled 923 adults with a history of locally advanced or metastatic TNBC. The dual primary endpoints of the trial were OS in the overall patient population and in patients with tumors that have qualifying alterations in the PI3K/AKT pathway. The safety profile of the combination of Truqap and chemotherapy was consistent with known data, showing no new safety concerns. AstraZeneca intends to share the full data from the study at a later date.
AstraZeneca states that TNBC is one of the most difficult-to-treat cancers due to the limited number of targeted biomarker treatments, with chemotherapy remaining the primary treatment. Reportedly, IK3CA, AKT1, and PTEN mutations affect around 35% of TNBC patients. Overall, breast cancer is the second most common cancer worldwide and one of primary drivers of cancer death.1
According to WebMD, approximately 60% of patients with TNBC will survive over five years without disease, but for an estimated four in 10 women will experience rapid recurrence. TNBC grows quicker than other breast cancers, with one study finding that it grows by 1% each day from diagnosis to surgery, compared to 0.859% for HER2-positive breast cancer. By the time it has been found, it is likely that TNBC has spread beyond the breast, and it has a higher probability of being more fatal within the first five years of treatment.2
“We are committed to advancing science for patients in some of the most challenging cancers, including this heterogeneous subtype of breast cancer. While we are disappointed in the CAPItello-290 outcome, these results will further our understanding of the role of the PI3K/AKT pathway in breast cancer as we continue our clinical research across the Truqap clinical development program and across our pipeline,” said Susan Galbraith, EVP, Oncology R&D, AstraZeneca, in the press release.
References
1. Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer. AstraZeneca. June 18, 2024. Accessed June 19, 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html
2. Triple-Negative Breast Cancer (TNBC). WedMD. February 20, 2024. Accessed June 19, 2024. https://www.webmd.com/breast-cancer/triple-negative-breast-cancer
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
